Methylprednisolone for COVID-19 Patients Admitted to a Tertiary Care Hospital: A Single-Centre Study.
| Autor: | Ahmad B; Endocrinology and Diabetes, Pak-Emirates Military Hospital Rawalpindi, Rawalpindi, PAK., Manzar A; Internal Medicine, Pak-Emirates Military Hospital, Rawalpindi, PAK., Khrshid S; Internal Medicine, Pak-Emirates Military Hospital, Rawalpindi, PAK., Ul Hassan N; Internal Medicine, Combined Military Hospital, Rawalpindi, PAK., Muhammad A; Dermatology, Pak-Emirates Military Hospital, Rawalpindi, PAK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2021 Sep 03; Vol. 13 (9), pp. e17693. Date of Electronic Publication: 2021 Sep 03 (Print Publication: 2021). |
| DOI: | 10.7759/cureus.17693 |
| Abstrakt: | Background: The role of various corticosteroids in the management of COVID-19 is evolving. Following an initial lack of evidence, the relatively novel data, supporting the survival benefit to severe and critical COVID-19 patients, is of limited scale. Materials and Methods: This retrospective study observed medical records and disease outcomes of 200 patients with moderate, severe and critical COVID-19 receiving methylprednisolone (MP). The dose of methylprednisolone was 0.5 to 2 mg per kg in these patients. Results: Median age of presentation was 59 years. The median duration of symptoms at presentation was five days. The most common presenting symptoms were cough (77.5%), fever (67.5%) and shortness of breath (63.5%). Majority of patients (85%) presented in the first week of illness. One or more comorbidities were present in 75% of patients. Complications seen in the study cohort were cytokine release syndrome (CRS) 92 (46%), acute respiratory distress syndrome (ARDS) 44 (22%) and multi-organ dysfunction 17 (8.5%). The median time for initiation of corticosteroid therapy was four hours. Overall survival (OS) in patients receiving methylprednisolone was 83.5%. The OS for patients with moderate, severe and critical diseases was 97.8%, 86.2% and 62%, respectively (p<0.001). Conclusion: Steroids like methylprednisolone are useful in COVID-19 admitted patients and provide excellent survival outcomes. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Ahmad et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|